Companies /Healthcare

Mckesson Corporation

NYSE: MCK Medical Distribution
$890.75
▼ $5.91 (−0.66%) today
Markets closed · 4:58pm ET

Q1 2027 Earnings

Reported Aug 5, 2026, 4:06pm ET · SEC source
$9.93
Beat +4.14%
EPS · est. $9.54 Adjusted
$105.4B
Beat +1.58%
Revenue · est. $103.7B
5 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−4%−2%0+2%Aug 5Aug 6report 4:06pm ETearnings−0.2%−0.4%
−4%−2%0+2%Aug 5Aug 6earnings−0.2%−0.4%
MCK −0.4%S&P 500 −0.2%
−4%−2%0+2%Aug 5Aug 6report 4:06pm ETearnings−0.1%−0.4%
−4%−2%0+2%Aug 5Aug 6earnings−0.1%−0.4%
MCK −0.4%NASDAQ −0.1%
−6%−3%0Aug 4Aug 13report 4:06pm ETearnings+0.9%−4.6%
−6%−3%0Aug 4Aug 13earnings+0.9%−4.6%
MCK −4.6%S&P 500 +0.9%
−6%−3%0+3%Aug 4Aug 13report 4:06pm ETearnings+2.2%−4.6%
−6%−3%0+3%Aug 4Aug 13earnings+2.2%−4.6%
MCK −4.6%NASDAQ +2.2%
−0.67%
Day of report
−0.21%
Next session
−1.69%
One week

Did MCK Beat Earnings? Q1 2027 Results

McKesson delivered a broad-based beat in its fiscal first quarter of 2027, with adjusted EPS of $9.93 clearing the $9.54 consensus estimate by 4.14% and revenue of $105.38 billion topping expectations by 1.58% on 7.7% year-over-year growth, extending the company's streak of beating consensus EPS estimates to four consecutive quarters. The standout driver was the Oncology & Multispecialty segment, which posted 33% revenue growth to $14.22 billion and 41% adjusted operating profit growth to $405.00 million, while North American Pharmaceutical revenues climbed to $86.77 billion with adjusted operating profit rising 19% to $894.00 million on specialty distribution strength. Notably, analysts heading into the print had flagged uncertainty around revenue consistency after a prior-quarter miss, making the clean top- and bottom-line beat all the more meaningful. Looking ahead, McKesson raised its full-year fiscal 2027 adjusted EPS guidance to $44.20 to $45.00, reflecting 13% to 15% growth versus the prior year, as management cited sustained operational momentum across its core distribution businesses.

Key Takeaways
  • Increased prescription transaction volumes, including higher specialty product volumes
  • Growth in distribution of specialty products to health systems and strategic accounts
  • Timing of new product launches benefiting North American Pharmaceutical
  • Growth in provider solutions and specialty distribution in Oncology & Multispecialty, including acquisition contributions
  • Higher demand for access solutions in Prescription Technology Solutions
  • Lower share count from aggressive share repurchase program
  • Lower contributions from branded pharmaceuticals partially offset revenue growth

“McKesson delivered a strong start to fiscal 2027, underscored by momentum across the enterprise and disciplined execution against our strategic priorities. Our first quarter performance exceeded our expectations, highlighted by 20% growth in Adjusted Earnings per Diluted Share. It demonstrates the strength of our core distribution businesses, continued growth in oncology and multispecialty, and solid execution across our biopharma services platform.”

McKesson CEO, on the earnings call

Forward Guidance & Outlook

McKesson raised its fiscal 2027 full-year Adjusted Earnings per Diluted Share guidance to $44.20–$45.00 from the previous range of $43.80–$44.60, indicating 13%–15% growth compared to the prior year. The raise reflects strong first quarter performance and sustainable operational momentum. The company does not provide forward-looking guidance on a GAAP basis. Additional modeling considerations will be provided in the earnings call presentation.

MCK YoY Financials

Q1 2027 vs Q1 2026 · SEC filings Q1 2026 Q1 2027
$0$30.0B$60.0B$90.0B$97.8B$105.4BRevenue$3.3B$3.7BGross Profit$1.0B$1.3BOperating Income$784.0M$614.0MNet Income
$0$30.0B$60.0B$90.0BRevenueGross ProfitOperating IncomeNet Income

MCK Revenue by Segment

North American Pharmaceutical$86.8B+5.0%
Oncology & Multispecialty$14.2B+33.0%
Medical-Surgical Solutions$2.8B+4.0%
Prescription Technology Solutions$1.6B+9.0%

Figures from SEC filings and company reports. Not investment advice.